Morgan Stanley analyst wants to move to the sidelines on Jazz Pharmaceuticals PLC JAZZ as the stock has gained around 34 percent year-to-date and approached his price target of $183. Morgan Stanley's David Risinger downgraded the stock from Overweight to Equal-Weight. SourceUpside starts to lose it's force, stochastics are getting closer to the overbought zone. the price will test the lower edge soon. $JAZZ, Jazz Pharmaceuticals plc / D